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AF = activation function; AIB = amplified in breast cancer; AP = activating protein; EGF = epidermal growth factor; ER = estrogen receptor; ERK =
extracellular signal-regulated kinase; IGF = insulin-like growth factor; MAPK = mitogen-activated protein kinase; USF = upstream stimulatory factor.
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Abstract
Estrogen and its receptor (ER) are critical for development and
progression of breast cancer. This pathway is targeted by
endocrine therapies that either block ER functions or deplete ER’s
estrogen ligand. While endocrine therapies are very effective, de
novo and acquired resistance are still common. Laboratory and
clinical data now indicate that bidirectional molecular crosstalk
between nuclear or membrane ER and growth factor receptor
pathways such as HER2/neu is involved in endocrine resistance.
Preclinical data suggest that blockade of selected growth factor
receptor signaling can overcome this type of resistance, and this
strategy is already being tested in clinical trials
Introduction
Estrogen receptors (ERs) play a key role in normal breast
development and in the development and progression of
breast cancer. Endocrine therapy for this disease, which had
its start more than 100 years ago when patients were first
treated with ovarian ablation [1], blocks the function of ERs
and thereby represents the first molecularly targeted therapy
for cancer. Long-term studies of patients treated with
adjuvant endocrine therapy suggest that this therapy is
curative in many patients. Now, many types of endocrine
therapy are available that inhibit the function of ERs in
different ways. In addition to ovarian ablation, selective ER
modulators such as tamoxifen bind ERs and partially block
their function [2]. Selective ER downregulators such as
fulvestrant completely block the function of ERs and down-
regulate the receptor proteins [3]. Finally, aromatase
inhibitors in postmenopausal women reduce estrogen to very
low levels – a strategy that may be the most effective
endocrine therapy used today [4,5].
However, endocrine therapies do not always work in patients,
despite the presence of ERs in their tumors [6]. Some tumors
are initially inhibited by endocrine therapy only to develop
acquired resistance with prolonged treatment. Other tumors
are  de novo resistant to endocrine therapy. Clinical
experience indicates that tumors resistant to one form of
therapy may still be sensitive to other hormonal treatments
[7], suggesting that resistance does not always indicate
global estrogen independence; resistance can be treatment
specific. Insights into the mechanisms of endocrine therapy
resistance have come from provocative studies on the biology
of ERs and the various signaling pathways in the cell with
which they communicate. Potential strategies to overcome
this resistance have been successful in preclinical models
and are now being tested in patients.
Structure and function of estrogen receptors
ERs are members of a large family of nuclear transcriptional
regulators that are activated by steroid hormones such as
estrogen [8]. The ERs exist as two isoforms, α and β, that are
encoded by two different genes [9]. These receptor proteins
have a similar structure but evidence indicates that they have
very different functions. ER proteins consist of a DNA binding
region and at least two transcriptional activation functions
(AFs) known as AF-1 and AF-2 [10]. A ligand binding domain
that interacts with estradiol is also located in the AF-2 region
[10,11]. The DNA binding domain of ERs allows the
receptors to bind to specific sequences in the promoters of
estrogen-regulated genes. AF-1 and AF-2 are important
domains for regulating transcription of these genes; AF-1 is
constitutively active but is enhanced by growth factor
signaling [12], whereas AF-2 is ligand-depend-active with
estrogen but not with tamoxifen [13].
Although ER-α and ER-β are both expressed in normal
mammary gland, it appears that ER-α, but not ER-β, is critical
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for normal gland development [14]. A dramatic increase in
ER-α content is observed in premalignant hyperproliferative
breast lesions and in many breast cancers compared with
normal mammary glands [15]. These observations are
consistent with the crucial role of the ER-α isoform in breast
cancer etiology and progression, and with the role played by
estrogens as tumor promoters. Growing evidence suggests
that ER-β may antagonize the function of ER-α, and high
levels of ER-β are associated with a more favorable response
to tamoxifen treatment [16]. However, the overall role of ER-β
in regulating breast cancer is yet to be defined, and therefore
further discussion in this review focuses mostly on ER-α.
Classical ER-α α function
Classically, ER-α regulates the expression of specific genes
in the nucleus. This function is sometimes referred to as
nuclear initiated steroid signaling [17]. Estrogen binding to
ER-α results in phosphorylation of the receptor protein,
dissociates chaperone proteins such as heat shock protein
90, and induces a change in protein conformation [11]. This
‘activated’ ER-α then dimerizes with another receptor protein
and the dimer binds to specific DNA sequences sometimes
called estrogen response elements in the promoter region of
estrogen responsive genes (Fig. 1a) [10]. This complex then
recruits a variety of coregulatory proteins such as amplified in
breast cancer 1 (AIB1 or SRC3), which function as co-
activators to enhance transcription of genes [18]. However,
estrogen bound ER-α is also capable of downregulating
expression of many genes [19]. Downregulation of gene
expression by estrogen may be explained by the recruitment
of corepressor proteins to the ER complex at certain gene
promoter sequences.
The coregulatory proteins complexed with ER-α on the
promoters of target genes are very important for the function
of ER-α [20,21]. Coactivators recruit other proteins including
acetyltransferases, which alter chromatin structure to
facilitate transcription [20-22]. AIB1 is a very important ER-α
coactivator protein and could even function as an oncogene
when overexpressed in preclinical models [23]. Reducing the
level of AIB1 impedes ER-α function and can inhibit the
growth of human breast tumor xenografts in mice [24]. AIB1
is also important in breast cancer in patients. It is
overexpressed in 65% of breast cancers and is occasionally
gene-amplified, suggesting that it plays an important role in
the development and progression of breast cancer [25,26].
Preclinical studies and clinical studies in patients suggest
that high levels of AIB1 may contribute to tamoxifen
resistance by enhancing the estrogen agonist activity of the
drug [27-29]. This may be particularly true in tumors that also
express high levels of HER2. Kinases activated by HER2
phosphorylate both ER and AIB1, resulting in an increase in
ER-α activity [29]. In this situation, tamoxifen-bound ER-α
may recruit coactivators such as AIB1 rather than
corepressors, resulting in tamoxifen-stimulated growth as a
mechanism for resistance to the drug.
ER-α has also been shown to modulate gene expression in
other ways. Through protein–protein interactions ER can bind
to transcriptional complexes on other regulatory DNA
sequences such as activating protein (AP)-1, Sp1, and
upstream stimulatory factor (USF) sites, as well as other
poorly defined promoter regions that are not typical estrogen
response elements (Fig. 1b) [30-33]. In this circumstance
ER-α is not the primary transcription factor binding DNA but it
is tethered to other transcription factor proteins such as c-jun
or c-fos. It then functions as a coactivator protein by
stabilizing DNA binding of the transcription complex or by
recruiting other coactivator proteins to these complexes
[34,35]. Several genes important for tumor cell proliferation
and survival may be regulated by estrogen in this way, and
data suggest that modulation of gene expression at AP-1
sites may be the most critical element in estrogen-mediated
tumor growth [30,36].
Through these direct transcriptional mechanisms, estrogen
regulates the expression of hundreds of genes, many of
which are important for cell proliferation, antiapoptosis,
invasion and metastasis, and angiogenesis. c-Myc, vascular
endothelial growth factor, bcl-2, insulin-like growth factor
(IGF)-R1, insulin receptor substrate-1, transforming growth
factor-α, cyclin-D1, and IGF-2 are all regulated by estrogen
[34,37-41]. Downregulation of expression of these and other
genes and/or upregulation of genes related to apoptosis or
cell cycle inhibition may explain the curative potential of
adjuvant endocrine therapy. Altered gene expression may
also contribute to certain forms of endocrine therapy
resistance. As mentioned above, the ER-α coactivator AIB1
Figure 1
Nuclear ER-α functions. (a) Enhanced transcription of genes with an
estrogen response element (ERE) in the promoter. (b) Enhanced
transcription of genes by modifying activity of transcription complexes at
other promoter sites (activator protein [AP]-1). AIB, amplified in breast
cancer; At, acetyltransferase; E, estradiol; ER, estrogen receptor-α.207
can bind to tamoxifen-bound ER-α complexes under some
circumstances, potentially reducing the estrogen antagonist
activity of the drug [29]. Increased AP-1 transcriptional
activity has been identified in preclinical models and in
patients with tamoxifen resistance [42,43]. More recent data
suggest that ER-α crosstalk with growth factor receptor
signaling pathways can modulate ER-α transcriptional activity
and may also contribute to resistance to tamoxifen or other
endocrine therapies [37,38].
Modification of transcriptional function of estrogen
receptor-α α by growth factor receptor signaling
Numerous growth factors and signaling molecules including
IGF-1, epidermal growth factor (EGF), heregulin, transforming
growth factor-α, dopamine, cyclic AMP, and membrane
permeable phosphatase inhibitors can all potentiate the
nuclear transcriptional effects of ER-α [40,44-46]. This
functional activation of ER-α results from direct phosphory-
lation of the ER-α protein at multiple sites, mainly at the AF-1
domain of the receptor [47], or from phosphorylation of ER-α
coactivators and corepressors [48]. This potentiation of ER-α
transcriptional activity due to phosphorylation of the ligand
independent AF-1 domain has been termed ligand
independent activation of ER-α, because it can occur in the
absence of estrogen. Multiple kinases involved in growth
factor, stress, or cytokine induced signaling can phos-
phorylate ER-α or its coregulatory proteins. These include
extracellular signal regulated kinase (ERK)1/2 and p38
mitogen-activated protein kinases (MAPKs), cyclin A/CDK-2,
CDK-7, c-Src, protein kinase A, pp90rsk1, Akt, IκB kinase,
and Jun amino terminal kinase [12,49-57]. Phosphorylation of
ER-α on these various sites affects protein dimerization, DNA
binding, ligand binding, nuclear localization, interactions with
coactivators and corepressors, and transcriptional activation
of genes [53,54,58-60]. Phosphorylation of ER-α coregulatory
proteins augments their activity on ER-α dependent
transcription, alters nuclear localization, affects their binding
to ER-α, and enhances their ability to recruit other
transcriptional coregulators [56,57,61]. Phosphorylation of
ER-α corepressors such as N-CoR also changes their affinity
for ER-α binding and modifies nuclear localization [62-64].
Thus, estrogen regulated gene expression is a coordinated
effort that depends on the receptor itself, its coregulatory
molecules, specific gene promoter sequences, the presence
or absence of other transcription factors, and input from a
variety of intracellular signaling pathways.
Membrane initiated (nongenomic) steroid signaling
ER-α functions not only as a transcription factor in the
nucleus; new data suggest that it can activate intracellular
signaling pathways outside the nucleus in the cytoplasm or
the plasma membrane (Fig. 2) [65]. It has been observed for
decades that estrogens can have very rapid effects on cells,
too rapid to invoke transcriptional mechanisms [66]. ERs
have been localized outside the nucleus by biochemical
analyses and by direct visualization using immuno-
cytochemistry or more sophisticated microscopy [67,68].
This nongenomic mode of action of ERs, as well as of other
steroid receptors, is also known as membrane-initiated
steroid signaling [17]. Many studies have now shown that
non-nuclear ER-α can exist in complexes with several
signaling molecules. Estrogen treatment of cells induces the
interaction between ER-α and IGF-1 receptor, which
activates signaling via ERK1/2 MAPK [69]. Estrogen also
stimulates association between ER-α and the p85 subunit of
phosphatidylinositol-3-OH kinase, resulting in its activation
[70]. ER-α interacts with other IGF signaling intermediates
including insulin receptor substrate 1 [71], which then
translocates to the nucleus where it may exist in transcription
complexes. ER-α can also interact with Shc, which links the
receptor to other signaling intermediates in the membrane
[72]. Thus, ER can complex with many elements in the
IGF-1R signaling cascade, thereby activating this pathway in
response to estrogen.
ER-α has also been shown to act as a G-protein-coupled
receptor at the membrane, where it binds to caveolin-1
(Fig. 2) [73-75]. In this way, ER-α can activate c-Src, in turn
leading to activation of metalloproteinases that then cleave
heparin binding EGF from the cell. This growth factor, acting
in an autocrine manner, binds EGF receptors on the cell
membrane, thereby activating downstream kinases such as
ERK1/2 MAPK and phosphatidylinositol-3-OH kinase. The
observation that tamoxifen, like estrogen, can activate
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Figure 2
Membrane or nongenomic functions of ER-α. Estrogen (E) or tamoxifen
binds membrane or cytoplasmic estrogen receptor (ER)-α to trigger
complexes with growth factor signaling molecules (such as insulin-like
growth factor [IGF]-R1, insulin receptor substrate [IRS]-1, or
phosphatidylinositol-3-OH kinase [PI3K]), which activate mitogen-
activated protein kinase (MAPK) or AKT. ER-α also acting as a G-
protein-coupled receptor activates Src, which activates matrix
metalloproteinase (MMP)-2, which cleaves heparin-binding epidermal
growth factor (Hb-EGF) from the membrane to bind and activate EGF
receptor (EGFR). EGFR also activates MAPK and AKT, which in turn
can phosphorylate and activate nuclear ER-α and amplified in breast
cancer (AIB)1, or directly contribute to tumor growth and survival
(dotted line).208
membrane ER suggests a plausible mechanism for tamoxifen
resistance in tumors in which this pathway is active. Pure ER
antagonists such as fulvestrant do not activate membrane ER
[69,75]. This type of ER-α activity may not be prominent in
most breast cancers that lack strong receptor tyrosine kinase
activity, but this activity can be potentiated in tumors that
overexpress tyrosine kinase receptors [29,76] or in those that
expresshigh levels of other proteins that bind ER-α and
sequester it in the cytoplasm or membrane. Such proteins as
modulator of nongenomic activity of ER (MNAR) [77-79] and
members of the metastasis associated gene family (MTA)
[80,81] may be important in membrane initiated ER-α
signaling by trapping it outside the nucleus.
Thus, ER-α may stimulate breast cancer growth in at least two
ways. It increases the expression of growth regulatory genes
via its transcriptional effects in the nucleus and it activates the
growth factor signaling cascade via its nongenomic or
membrane activity outside the nucleus. In some tumors,
particularly those with amplification of HER2 or overexpression
of other growth factor receptor tyrosine kinases, a vicious cycle
of cell proliferative and cell survival stimuli is initiated by the
binding of estrogen to its receptor. ER-α by a variety of
mechanisms activates the growth factor signaling cascade,
while at the same time the growth factor receptor kinase
cascade phosphorylates and activates ER-α and its
coregulating proteins. Membrane or nonnuclear ER-α signaling
has been described in experimental model systems and needs
to be confirmed in clinical breast cancer. Tumors with active
ER-α/growth factor receptor crosstalk, especially those that
are largely dependent on the membrane/non-nuclear ER-α
signaling, could be expected to be very dependent on estrogen
for growth and might then be highly responsive to treatment
with estrogen deprivation therapy, such as aromatase
inhibition. These tumors should also be responsive to selective
ER downregulators, such as fulvestrant, which function as
complete antagonists on both nuclear and non-nuclear ER
activities. Tamoxifen, on the other hand, because it activates
membrane ER-α signaling might not be as effective, and in fact
it might even stimulate growth of such tumors [29]. As
described below, clinical data do support these paradigms. An
understanding of these ER activities at the molecular level may
yield new strategies to prevent or overcome resistance to
tamoxifen and other forms of treatment.
Blocking estrogen receptor/growth factor
receptor crosstalk to overcome treatment
resistance
The molecular functions of ER-α and its crosstalk with growth
factor receptors are exploitable for treatment purposes.
Preclinical experimental models first suggested that tumors
overexpressing HER2, in addition to ER-α, might be
tamoxifen resistant [82]. Since then, the bulk of clinical
evidence indicates that patients with HER2-overexpressing
ER-α-positive breast cancers derive less benefit from
tamoxifen than do those with HER2-negative breast cancers
[29,83-85]. A recent clinical report [86] also suggested that
activation of ER-α function by growth factor signaling is
important for tamoxifen resistance. Tamoxifen-treated patients
whose tumors expressed high levels of both AIB1 and HER2
had extremely poor disease-free survival compared with
patients whose tumors overexpressed neither or only one of
the two proteins. This clinical observation makes biologic
sense because kinases activated downstream from HER2
phosphorylate and functionally activate AIB1 and ER-α,
thereby reducing the antagonist activity of the tamoxifen-
bound receptor.
Prospective trials in patients with metastatic disease also
suggest that tamoxifen resistance is associated with high
levels of expression of receptor tyrosine kinases such as
HER2 and EGF receptor [87]. Furthermore, because
resistance to selective ER modulators such as tamoxifen is
mediated, at least in part, via activation of the nongenomic
actions of ER, other hormonal treatments that can block this
ER activity should be effective second-line therapies for
patients whose tumors acquired resistance to tamoxifen.
Importantly, aromatase inhibitors and the ER downregulator
fulvestrant, which can deactivate both the genomic and the
nongenomic effects of ER, are indeed effective therapies in
tamoxifen resistant patients [7]. Finally, three studies in which
patients were given neoadjuvant endocrine therapy as initial
treatment further support these hypotheses [88-90]. Two of
these trials randomized patients to tamoxifen or an aromatase
inhibitor. Both found that tumor response to tamoxifen was
about half of that observed with the aromatase inhibitor in
tumors overexpressing HER2. The response rates were more
similar for tumors that were negative for HER2. In fact, the
response rates to the aromatase inhibitor in these two trials,
as well as in a third nonrandomized trial, were at least as high
or higher in tumors overexpressing HER2 than in HER2
negative tumors. These neoadjuvant trials do not provide data
on the duration of response to the aromatase inhibitors in
HER2 positive disease. Preclinical studies suggest that
growth factor receptor signaling can also contribute to
acquired resistance to estrogen deprivation therapies [91].
Nevertheless, the substantial initial tumor response in the
HER2 positive subset of patients suggests that these tumors
are indeed very dependent on estrogen for growth. Analysis
of completed large adjuvant trials with patients classified by
ER-α, progesterone receptor, and HER2 status are needed
to confirm the superior efficacy of aromatase inhibitors
compared with tamoxifen in such patients.
If the growth factor receptor tyrosine kinase signaling
pathway is involved in resistance to hormonal therapy, then
an obvious question is whether blockade of these pathways
can delay or overcome treatment resistance (Fig. 3). Compel-
ing data from in vitro and  in vivo experimental models
suggest that this strategy is worth testing in patients. In a
xenograft model of an ER-α positive, HER2 overexpressing
tumor, tamoxifen-stimulated growth mediated by growth
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factor receptor activation by nongenomic ER-α signaling is
the mechanism for de novo resistance [29]. Simultaneous
treatment of mice with the EGF receptor tyrosine kinase
inhibitor gefitinib blocked activation of HER2 signaling by
tamoxifen, reduced phosphorylation of ER-α and AIB1, and
completely restored tamoxifen’s antagonist activity on tumor
growth. Similar data have been reported in other experimental
models [85]. In a recent study [92], lapatinib – a dual EGF
receptor/HER2 tyrosine kinase inhibitor – effectively inhibited
the growth of non-HER2 overexpressing tumors that had
developed acquired resistance to tamoxifen. Gefitinib and
lapatinib are now in clinical trials to test the concept that
simultaneous treatment with growth factor inhibitors
combined with ER-targeted therapy is more effective than
either treatment by itself.
Conclusion
Although ER-α was discovered nearly 40 years ago,
scientists continue to unravel its complex role in cellular
function. It is clear that ER-α has multiple activities and that it
often does not act alone but rather in concert with other
signaling pathways that can modify its output. Some of these
pathways lead to specific changes in receptor activity that
contribute to resistance to hormonal therapies. Because
there are many signaling molecules that can modulate the
function of ERs, an accurate molecular profile of each
patient’s tumor will be required in the future to design the
optimal therapeutic approach by identifying the major
pathways that are working together to drive the growth of a
particular tumor. The fact that targeting ER-α by itself offers
long-term disease control in many patients that is tantamount
to cure indicates that the mechanisms regulating breast
cancer growth may not be as complicated as some may have
thought, and that accurate identification of the pathway or
pathways that regulate tumor cell survival and proliferation
and then blocking only those pathways may prove to be an
extraordinarily successful strategy.
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